Pieris Pharmaceuticals Stock News

First patient has been dosed for phase 2 study using PRS-343 for treatment of patients with HER2 gastric cancer. Part 1 safety portion of the phase 2a study using PRS-060 in patients with asthma has b

Pieris Pharmaceuticals (PIRS) said the first patient was dosed in a phase 2 study of cinrebafusp alfa (PRS-343) to treat HER2-expressing gastric cancer.The trial is evaluating

Investors in Pieris Pharmaceuticals, Inc. PIRS need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 18, 2021 $17.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market [] The post Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Dont? appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

Investors need to pay close attention to for Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.

Investors need to pay close attention to for Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.

Morgan Stanley lifted its position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) by 104.6% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,675,969 shares of the biotechnology companys stock after buying an additional 856,793 shares during the quarter. Morgan Stanley owned about 2.51% of Pieris Pharmaceuticals []

Cubist Systematic Strategies LLC acquired a new position in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 42,643 shares of the biotechnology companys stock, valued at approximately $163,000. Cubist Systematic Strategies LLC owned approximately 0.06% []

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) saw a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 694,000 shares, a decline of 75.4% from the October 31st total of 2,820,000 shares. Approximately 1.2% of the company’s shares are short sold. Based on an average trading volume of […]

Wall Street brokerages expect Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to report sales of $5.97 million for the current quarter, according to Zacks. Two analysts have provided estimates for Pieris Pharmaceuticals earnings, with the highest sales estimate coming in at $7.03 million and the lowest estimate coming in at $4.91 million. Pieris Pharmaceuticals reported sales of $1.88 []

BOSTON, MA / ACCESSWIRE / November 11, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® te

Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 0.00% and -49.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the st

BOSTON, MA / ACCESSWIRE / October 26, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® te

With so much chaos occurring on Wall Street, these lesser-known penny stocks to buy might fly profitably under the radar. The post 7 Penny Stocks to Buy to Sidestep the Noise on Wall Street appeared f

Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.

BOSTON, MA / ACCESSWIRE / October 6, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tech